Spiriva shows little aid to long-term lung function

Last Updated: 2008-10-06 17:01:57 -0400 (Reuters Health)

BOSTON (Reuters) - Spiriva, marketed by Pfizer and Boehringer Ingelheim, offered no advantage over an inhaled placebo for moderate-to-very-severe chronic obstructive pulmonary disease, or COPD, researchers reported on Sunday.  (More)